Vimarsana
Biggest News Aggregation in the World

Page 3 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

Phase 2 Study of Denifanstat Looks to Add First-in-Class Agent to HER2+Breast Cancer Treatment Armamentarium - Vimarsana News

Phase 2 Study of Denifanstat Looks to Add First-in-Class Agent to HER2+Breast Cancer Treatment Armamentarium

Phase 2 trial investigators hope denifanstat can be a key component in restoring sensitivity to HER2- positive metastatic breast cancer treatments.

KVA12123 Showcases Early Tolerability in Advanced Solid Tumors - Vimarsana News

KVA12123 Showcases Early Tolerability in Advanced Solid Tumors

KVA12123 demonstrated early signals of on-target activity and tolerability at all dose levels examined to date in patients with advanced solid tumors.

Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300 - Vimarsana News

Tyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300

- Initiated SURF201 Phase 1 Study; dosed first patient with TYRA-200- - Cleared multiple dose cohorts in SURF301 and continues to dose escalate with TYRA-300-- Received FDA feedback on TYRA-300...

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit - Vimarsana News

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Company to also share progress with cell-based virotherapy platforms for advanced solid tumors ...

Dragonfly Therapeutics Initiates Phase 1 1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors - Vimarsana News

Dragonfly Therapeutics Initiates Phase 1 1b Study of its IL-2 Immunotherapy in Patients with Advanced Solid Tumors

The company announces the first patient dosed in a Phase 1/1b clinical trial evaluating its novel IL-2 cytokine, DF6215, the seventh Dragonfly-developed drug ...

Source: zazoom.it